Molecular Characteristics of Early-Onset Colorectal Cancer According to Detailed Anatomical Locations: Comparison With Later-Onset Cases

1Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA;

2Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;

3Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA;

4Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri, USA;

5Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA;

6Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA;

7Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA;

8Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA;

9Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;

10Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA;

11Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA;

12Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany;

13Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;

14German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany;

15Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia;

16University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia;

17Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, Victoria, Australia;

18Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany;

19University Medical Centre Hamburg-Eppendorf, University Cancer Centre Hamburg (UCCH), Hamburg, Germany;

20Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada;

21Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France;

22Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia;

23Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia;

24Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia;

25Oncology Data Analytics Program, Catalan Institute of Oncology (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain;

26CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain;

27 Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain;

28Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain;

29Department of Epidemiology, University of Washington, Seattle, Washington, USA;

30Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;

31Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, Arizona, USA;

32Division of Research, Kaiser Permanente Northern California, Oakland, California, USA;

33Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA;

34Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA;

35Departments of Cancer Biology and Genetics and Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA;

36Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden;

37Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden;

38Memorial University of Newfoundland, Discipline of Genetics, St. John's, Canada;

39Ontario Institute for Cancer Research, Toronto, Ontario, Canada;

40Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA;

41Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA;

42Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, Massachusetts, USA.

Correspondence: Shuji Ogino, MD, PhD, MS. E-mail: [email protected].

SUPPLEMENTARY MATERIAL accompanies this paper at https://links.lww.com/AJG/C852

Use of Standardized Official Symbols: We use HUGO (Human Genome Organization)–approved official symbols (or root symbols) for genes and gene products, including BRAF, EGFR, KRAS, MLH1, MSH2, MSH6, and PMS2, all of which are described at www.genenames.org. Gene symbols are italicized whereas symbols for gene products are not italicized.

*Tomotaka Ugai, Koichiro Haruki, Tabitha A. Harrison, Yin Cao contributed equally as cofirst authors.

†Jonathan A. Nowak, Amanda I. Phipps, Ulrike Peters, Shuji Ogino contributed equally as colast authors.

留言 (0)

沒有登入
gif